Literature DB >> 7863360

The role of the sickness funds in the Belgian health care market.

W Nonneman1, E van Doorslaer.   

Abstract

This article reviews some of the salient features of the Belgian health care finance and delivery system. Special attention is paid to the role played by the third-party payers, i.e. the Health Insurance Associations (HIAs) in administering the compulsory national health insurance program. It is shown how, despite extensive government regulation, the markets for GP, specialist and hospital services exhibit fierce competition of the non-price variety. Next, the paper considers the three problems perceived to be the most pressing ones at present: (i) the problem of raising sufficient revenues to cover the public share of health expenditures; (ii) the (related) cost containment problem; and (iii) the problem of ensuring efficiency through appropriate incentive mechanisms. Finally, two recently proposed options for reform are discussed and complemented with a third proposal based on the ideas of regulated competition. It is concluded that strengthening the role of the third-party payers remains crucial in any attempt to reshape the system to make it efficient and affordable while keeping it equitable.

Mesh:

Year:  1994        PMID: 7863360     DOI: 10.1016/0277-9536(94)90242-9

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  3 in total

1.  Risk adjustment and the fear of markets: the case of Belgium.

Authors:  E Schokkaert; C Van de Voorde
Journal:  Health Care Manag Sci       Date:  2000-02

2.  Drug use in relation to clinical activities as an instrument for prospective drug budgeting. The Belgian experience.

Authors:  M C Closon; R Crott; D Even-Adin
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

3.  Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.

Authors:  Niels Neymark; Thierry Gorlia; Ines Adriaenssen; Benoit Baron; Martine Piccart
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.